ClinConnect ClinConnect Logo
Search / Trial NCT03284099

Bedtime ACEIs/ARBs Versus Morning ACEIs/ARBs for Reverting Non-dipping Hypertension

Launched by CHINESE UNIVERSITY OF HONG KONG · Sep 13, 2017

Trial Information

Current as of August 20, 2025

Terminated

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients who are taking an ACEI or an ARB
  • \>18 years of age
  • Chinese and
  • Received a diagnosis of primary HT.
  • Exclusion Criteria:
  • Severe HT as defined by a clinic systolic BP ≥180 mmHg and/or diastolic BP ≥ 110 mmHg
  • allergic reaction or intolerance to the current ACEI or ARB
  • unable to provide consent
  • pregnancy
  • night-time worker
  • occupational drivers since patients will be asked not to move during BP measurements, which may induce potential danger in driving
  • taking anti-coagulants to avoid causing bruises when using ABPM
  • known atrial fibrillation since ABPM use has not been validated in this group
  • known hyperkalemia
  • ABPM discovered hypotension (mean SBP \< 100 and/or mean DBP \< 60) because these patients may need to stop their medications
  • Reported sleep time of \<4 hours per night (at least seven readings are recommended during sleep for an ABPM recording to be valid, and a sleeping time \< 4 hours is unlikely to generate valid results).

About Chinese University Of Hong Kong

The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.

Locations

Hong Kong, , Hong Kong

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials